ctDNA-Guided Cetuximab or Bevacizumab Plus Trifluridine/Tipiracil in RAS/BRAF Wild-Type mCRC

This trial is using circulating tumor DNA (ctDNA) — tiny fragments of cancer DNA found in the blood — to guide the choice between two targeted drug combinations as later-line treatment for metastatic colorectal cancer that started as RAS/BRAF wild-type (without those specific mutations). **You may be eligible if...** - You have metastatic colorectal cancer with confirmed RAS/BRAF wild-type status - You previously had at least 6 months of benefit from a cetuximab-based first-line regimen, then progressed - You have already received at least one further line of treatment after that progression **You may NOT be eligible if...** - Your colorectal cancer has developed RAS mutations detected in blood tests (ctDNA) - Your overall health is significantly compromised - You have had prior treatment with trifluridine/tipiracil (TAS-102) - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.